Tumor resection cavity administered iodine-131-labeled antitenascin 81C6 radioimmunotherapy in patients with malignant glioma: neuropathology aspects.
Publication
, Journal Article
McLendon, RE; Akabani, G; Friedman, HS; Reardon, DA; Cleveland, L; Cokgor, I; Herndon, JE; Wikstrand, C; Boulton, ST; Friedman, AH; Bigner, DD ...
Published in: Nucl Med Biol
May 2007
INTRODUCTION: The neurohistological findings in patients treated with targeted beta emitters such as (131)I are poorly described. We report a histopathologic analysis from patients treated with combined external beam therapy and a brachytherapy consisting of a (131)I-labeled monoclonal antibody (mAb) injected into surgically created resection cavities during brain tumor resections. METHODS: Directed tissue samples of the cavity walls were obtained because of suspected tumor recurrence from 28 patients. Samples and clinical follow-up were evaluated on all patients (Group A) based on total radiation dose received and a subset of these (n=18; Group B, proximal therapy subset) who had received external beam therapy within
Duke Scholars
Published In
Nucl Med Biol
DOI
ISSN
0969-8051
Publication Date
May 2007
Volume
34
Issue
4
Start / End Page
405 / 413
Location
United States
Related Subject Headings
- Treatment Outcome
- Tenascin
- Survival Analysis
- Radiopharmaceuticals
- Radiometry
- Radioimmunotherapy
- Nuclear Medicine & Medical Imaging
- Neoplasms
- Neoplasm Recurrence, Local
- Necrosis
Citation
APA
Chicago
ICMJE
MLA
NLM
McLendon, R. E., Akabani, G., Friedman, H. S., Reardon, D. A., Cleveland, L., Cokgor, I., … Zalutsky, M. R. (2007). Tumor resection cavity administered iodine-131-labeled antitenascin 81C6 radioimmunotherapy in patients with malignant glioma: neuropathology aspects. Nucl Med Biol, 34(4), 405–413. https://doi.org/10.1016/j.nucmedbio.2007.01.009
McLendon, Roger E., Gamal Akabani, Henry S. Friedman, David A. Reardon, Linda Cleveland, Ilkcan Cokgor, James E. Herndon, et al. “Tumor resection cavity administered iodine-131-labeled antitenascin 81C6 radioimmunotherapy in patients with malignant glioma: neuropathology aspects.” Nucl Med Biol 34, no. 4 (May 2007): 405–13. https://doi.org/10.1016/j.nucmedbio.2007.01.009.
McLendon RE, Akabani G, Friedman HS, Reardon DA, Cleveland L, Cokgor I, et al. Tumor resection cavity administered iodine-131-labeled antitenascin 81C6 radioimmunotherapy in patients with malignant glioma: neuropathology aspects. Nucl Med Biol. 2007 May;34(4):405–13.
McLendon, Roger E., et al. “Tumor resection cavity administered iodine-131-labeled antitenascin 81C6 radioimmunotherapy in patients with malignant glioma: neuropathology aspects.” Nucl Med Biol, vol. 34, no. 4, May 2007, pp. 405–13. Pubmed, doi:10.1016/j.nucmedbio.2007.01.009.
McLendon RE, Akabani G, Friedman HS, Reardon DA, Cleveland L, Cokgor I, Herndon JE, Wikstrand C, Boulton ST, Friedman AH, Bigner DD, Zalutsky MR. Tumor resection cavity administered iodine-131-labeled antitenascin 81C6 radioimmunotherapy in patients with malignant glioma: neuropathology aspects. Nucl Med Biol. 2007 May;34(4):405–413.
Published In
Nucl Med Biol
DOI
ISSN
0969-8051
Publication Date
May 2007
Volume
34
Issue
4
Start / End Page
405 / 413
Location
United States
Related Subject Headings
- Treatment Outcome
- Tenascin
- Survival Analysis
- Radiopharmaceuticals
- Radiometry
- Radioimmunotherapy
- Nuclear Medicine & Medical Imaging
- Neoplasms
- Neoplasm Recurrence, Local
- Necrosis